An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

References

• Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992–2006. Sex Transm Infect 2009; 85:416-9; PMID:19273479; http://dx.doi.org/10.1136/sti.2008.033902
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Dave B, Mindel A, McPhie KA, Chung C, Marks C, Dwyer DE. Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex Transm Infect 2006; 82:255-9; PMID:16731681; http://dx.doi.org/10.1136/sti.2005.018176
   PubMed Web of Science ®Google Scholar
• Tran T, Druce JD, Catton MC, Kelly H, Birch CJ. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004; 80:277-9; PMID:15295125; http://dx.doi.org/10.1136/sti.2004.009753
   PubMed Web of Science ®Google Scholar
• Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83; PMID:16327322; http://dx.doi.org/10.1097/01.aids.0000198081.09337.a7
   PubMed Web of Science ®Google Scholar
• Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 2012; 10:228-37; PMID:22384842; http://dx.doi.org/10.2174/157016212800618156
   PubMed Web of Science ®Google Scholar
• Coleman JL, Shukla D. Recent advances in vaccine development for herpes simplex virus types I and II. Hum Vaccin Immunother 2013; 9:729-35; PMID:23442925; http://dx.doi.org/10.4161/hv.23289
   PubMed Web of Science ®Google Scholar
• Chung E, Sen J. The ongoing pursuit of a prophylactic HSV vaccine. Rev Med Virol 2012; 22:285-300; PMID:22396215; http://dx.doi.org/10.1002/rmv.1709
   PubMed Web of Science ®Google Scholar
• Kaufmann JK, Flechtner JB. Evolution of rational vaccine designs for genital herpes immunotherapy. Curr Opin Virol 2016; 17:80-6; PMID:26896782; http://dx.doi.org/10.1016/j.coviro.2016.01.021
   PubMed Web of Science ®Google Scholar
• Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331-40; PMID:10432030; http://dx.doi.org/10.1001/jama.282.4.331
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Rosenthal SL. Genital herpes simplex virus infection in the adolescent: special considerations for management. Paediatr Drugs 2002; 4:291-7; PMID:11994034; http://dx.doi.org/10.2165/00128072-200204050-00002
   PubMedGoogle Scholar
• Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43; PMID:22216840; http://dx.doi.org/10.1056/NEJMoa1103151
   PubMed Web of Science ®Google Scholar
• Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Investig 2011; 121:4600-09; PMID:22133885; http://dx.doi.org/10.1172/JCI57148
   PubMed Web of Science ®Google Scholar
• Lee AJ, Ashkar AA. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development. Curr Opin Infect Dis 2012; 25:92-9; PMID:22143115; http://dx.doi.org/10.1097/QCO.0b013e32834e9a56
   PubMed Web of Science ®Google Scholar
• Long D, Skoberne M, Gierahn TM, Larson S, Price JA, Clemens V, Baccari AE, Cohane KP, Garvie D, Siber GR, et al. Identification of novel virus-specific antigens by CD4(+) and CD8(+) T cells from asymptomatic HSV-2 seropositive and seronegative donors. Virology 2014; 464-465:296-311; PMID:25108380
   PubMed Web of Science ®Google Scholar
• Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. A Vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012; 30:7046-51; PMID:23041125; http://dx.doi.org/10.1016/j.vaccine.2012.09.057
   PubMed Web of Science ®Google Scholar
• Dutton JL, Li B, Woo WP, Marshak JO, Xu Y, Huang ML, Dong L, Frazer IH, Koelle DM. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PloS one 2013; 8:e76407; PMID:24098493; http://dx.doi.org/10.1371/journal.pone.0076407
   PubMed Web of Science ®Google Scholar
• Zhang X, Castelli FA, Zhu X, Wu M, Maillère B, BenMohamed L. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vaccine Immunol 2008; 15:1436-49; PMID:18667634; http://dx.doi.org/10.1128/CVI.00123-08
   PubMed Web of Science ®Google Scholar
• Prazeres DM, Monteiro, GA. Plasmid Biopharmaceuticals. Microbiology spectrum 2014; 2:1–18; PMID:26104457
   PubMedGoogle Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Exp Rev Vaccin 2008; 7:175-91; PMID:18324888; http://dx.doi.org/10.1586/14760584.7.2.175
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Kinnear E. Using Plasmids as DNA Vaccines for Infectious Diseases. Microbiol Spectrum 2014; 2:1–16; PMID:26104452
   PubMedGoogle Scholar
• Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC, NIAID HIV Vaccine Trials Network. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine 2015; 33:2347-53; PMID:25820067; http://dx.doi.org/10.1016/j.vaccine.2015.03.036
   PubMed Web of Science ®Google Scholar
• Enama ME, Ledgerwood JE, Novik L, Nason MC, Gordon IJ, Holman L, Bailer RT, Roederer M, Koup RA, Mascola JR, et al. Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). PloS one 2014; 9:e91366
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-1797; PMID:22956656; http://dx.doi.org/10.1128/CVI.05663-11
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40:86-97; PMID:16997717; http://dx.doi.org/10.1016/j.ymeth.2006.05.022
   PubMed Web of Science ®Google Scholar
• Nelson J, Rodriguez S, Finlayson N, Williams J, Carnes A. Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process. Hum Vaccin Immunother 2013; 9:2211-5; PMID:23899469; http://dx.doi.org/10.4161/hv.25048
   PubMed Web of Science ®Google Scholar